Autologous Serum and Serum Components

Abstract

Dry eye syndrome is a multifactorial condition on the tear and ocular surface. Autologous serum eye drop is an effective method for treating dry eye. Autologous serum eye drops are now widely used by specialists since a first report in 1975. The results of a systematic study showed that the efficacy of autologous serum eye drops remains ambiguous because its preparation methods and clinical application have not been standardized. To elucidate the efficacy of autologous serum eye drops, well-designed, large-scale, high-quality randomized controlled trials need to be conducted with standardized treatment and use. Since serum components are partially similar to tear components, autologous serum eye drops improve dry eye by supplying tear components such as growth factors, proteins, and vitamins. Adding to the evidence based on the treatment of dry eye, we have found a new treatment candidate from serum: selenoprotein P (SeP). The efficacy of SeP as a treatment for dry eye was revealed by applying SeP eye drops to a dry eye rat model. Compared with phosphate-buffered saline treatment, SeP eye drops significantly reduced the fluorescein score of the cornea and suppressed the oxidative stress in the cornea, which is related to onset of dry eye, leading to improved corneal disorder. We have developed a new dry eye model caused by oxidative stress that will be used to screen candidate molecules for antioxidative activity.

Utilization of metabolic energy in treatment of ocular surface disorders: polyphosphate as an energy source for corneal epithelial cell proliferation

“…Impaired corneal regeneration remains an unresolved clinical problem in ophthalmology. In addition to lubricants, substances containing growth factors, such as autologous serum and hp-lysate, 42 have been clinically applied. Studies have been performed to standardize the hp-lysate for their active bio-ingredients with some success.…”

“…Studies have been performed to standardize the hp-lysate for their active bio-ingredients with some success. In the present study; we applied a frequently used concentration of 5% v/ v. 42 As a suitable concentration of polyP for the in vitro studies a range around 50 mg ml À1 has been determined. 24 However, the production of such products requires logistical effort and excludes patients with certain infectious diseases.…”

<p>Ocular Neuropathic Pain: An Overview Focusing on Ocular Surface Pains</p>

“…Further, autologous serum prevents apoptosis in corneal and conjunctival epithelium. 22,53 In cases where high intraocular pressure is causing pain, ocular hypotensive drugs are helpful.…”

Dry Eye Disease: A Review of Epidemiology in Taiwan, and its Clinical Treatment and Merits

“…Several studies have pointed out the great effectiveness of autologous serum for DED [148][149][150]. Autologous serum is potentially advantageous to treat many dry eye-related ocular surface disorders, such as Sjogren's syndrome, graft-versus-host disease, Stevens-Johnson syndrome, and ocular cicatricial pemphigoid.…”